Therapeutic target
Red blood cell proliferation (promotion of red blood cell growth).
Therapy recommendations
- Administration of erythropoietins (= causal therapy/causal therapy)Note: As long as the Hb value is > greater than 10, 0 g/dL, erythropoietins should not be given.
- Hb (hemoglobin/blood pigment) should be maintained in a range of 11-12 g/dl.
Erythropoietin (EPO)
Erythropoietin is a growth factor important for the formation of erythropoiesis (formation of red blood cells) during hematopoiesis (blood formation). In humans, it is predominantly formed in the kidney. Since it can no longer be formed sufficiently in kidney diseases such as renal insufficiency (kidney weakness) and other diseases such as tumors, it must be supplied to the body from the outside if there are signs of renal anemia. Recombinant preparations (biopharmaceuticals) are used for this purpose. Erythropoietins not only increase erythropoiesis (formation of erythrocytes/red blood cells), but also reduce left ventricular hypertrophy (pathological enlargement of the left ventricle) and improve CKD progression (progression of kidney disease).Side effect of the therapy is mainly the development of hypertension (high blood pressure).Caveat (Warning)! EPO administration may cause or worsen arterial hypertension (high blood pressure).
